Gyeongbuk Fisheries Technology Institute and Komipharm Sign Agreement to Reduce Damage from Flounder Disease
Predicted impact: Low· Actual: −23.3% vs sector, volume 1.3× normal (5 trading days)
Komipharm International코미팜
041960 · KOSDAQ · ₩041960 · 코미팜
₩8,680▲ ₩390 (4.70%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y +39.77%
- Market cap
- ₩648B
- Enterprise value
- ₩661B
- P/E
- —
- P/B
- 9.0×
- Dividend yield
- 0.0%
- ROE
- −3.6%
- Net margin
- −4.9%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−27.0% from the high
₩5,650Today: ₩8,360 – ₩8,870₩11,890
Returns
- 1W−8.7%
- 1M−12.3%
- 3M+29.9%
- 6M−12.6%
- YTD+23.6%
- 1Y+39.8%
- Volume today
- 181,174
- 0.6× the 20-day average
- Traded today
- ₩1.6B
- Listed shares
- 74,618,201
- EPS (12 months)
- −₩35
- Earnings yield −0.4%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 33 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.9% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Leveraged ETF flows
Estimated leveraged-ETF rebalance on Oct 28: buy ₩1B at the close (31.2% of 20-day average trading value)
On its 26 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 28.1% of trading value and pointed the same way 14 of 26 times.
- 2× KODEX KOSDAQ150 Leverage ₩928M
- -1× KODEX KOSDAQ150 Futures Inverse ₩52M
- 2× TIGER KOSDAQ150 Leverage ₩48M
- 2× RISE KOSDAQ150 Futures Leverage ₩9M
- -1× TIGER KOSDAQ150 Futures Inverse ₩1.7M
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
ETFs holding this
All ETFs →Held by 11 funds.
- KODEX KOSDAQ1500.2%
- KODEX KOSDAQ150 Leverage2×0.2%
- TIGER KOSDAQ1500.2%
- RISE KOSDAQ1500.2%
- TIGER KOSDAQ150 Leverage2×0.2%
- ACE KOSDAQ 1500.2%
- KIWOOM KOSDAQ1500.2%
- SOL KOSDAQ1500.2%
Estimated from the funds' index or underlying stock.
Komipharm International stock overview
Komipharm International (코미팜, KRX: 041960) is listed on KOSDAQ, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩8,680 on Oct 28, 2026, up 4.70% on the day, giving it a market value of ₩648B.
Key facts
- Market cap
- ₩648B
- Sector
- Biotech & Pharma
- Latest price change
- +4.70%
- As of
- Oct 28, 2026
- Main business
- , Ltd.
Quick answers about Komipharm International
- What does Komipharm International do?
- , Ltd. was founded in 1972 to develop and sell veterinary medicines. It produces and sells animal drugs, mainly vaccines such as foot-and-mouth disease and swine fever vaccines, and also provides clinical pathology testing services.
- What is the market cap of Komipharm International?
- The market capitalisation of Komipharm International was ₩648B at the close on Oct 28, 2026.
- Who are the largest shareholders of Komipharm International?
- According to the latest official filings, the largest reported holders are Yang Kyung-hoon (31.21%, as of Jan 23, 2025); Suseong Asset Management (3.79%, as of Sep 15, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (0.88%, as of Jul 31, 2026).
- When is the next earnings report from Komipharm International?
- Korean companies rarely announce results dates in advance. Based on when Komipharm International filed the same report in past years, its next 3q results is expected between Nov 1, 2026 and Nov 14, 2026.
- Does the National Pension Service own Komipharm International?
- Yes. The National Pension Service held 0.02% of Komipharm International shares as of Dec 31, 2023.
Company profile
Komipharm Co., Ltd. was founded in 1972 to develop and sell veterinary medicines. It produces and sells animal drugs, mainly vaccines such as foot-and-mouth disease and swine fever vaccines, and also provides clinical pathology testing services. The company is also developing human drugs, including the cancer and cancer-pain treatment PAX-1, which is in clinical trials in Australia, Taiwan, Korea, El Salvador and the United States. Its main manufacturing facilities are located in Siheung and Yesan, with a plant in Osong, Chungcheongbuk-do.
Written by AI from the company's latest annual report.
- Korean name
- 코미팜
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 양경훈, 문성철(각자 대표이사)
- Founded
- Sep 1972
- Listed
- Oct 2001
- Listed shares
- 74,618,201
- Fiscal year ends
- Month 12
- Website
- www.komipharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Recent filings
See all- Insider shareholding reportOct 27, 2026
- Amended: Major sales or supply contractSep 10, 2026
- Half-year report (Jun 2026)Aug 13, 2026
- Quarterly report (Mar 2026)May 14, 2026
- Amended: Major sales or supply contractApr 8, 2026
Titles in Korean until English translations are added.
Also known as: Komipharm International / 코미팜 / 041960 / KRX:041960
Source: KRX statistical information